https://scholars.lib.ntu.edu.tw/handle/123456789/565648
標題: | Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates | 作者: | Su H.-J. Chiu Y.-T. Chiu C.-T. Lin Y.-C. Wang C.-Y. Hsieh J.-Y. SHU-CHEN WEI |
關鍵字: | 2018; Inflammatory bowel disease; Update | 公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 期: | 7 | 起(迄)頁: | 1083-1092 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | The global incidence and prevalence of inflammatory bowel disease (IBD) has increased over the last 2-4 decades, likely because of the adoption of a more “western” lifestyle as well as improved detection and awareness, and Taiwan is no exception. To characterize the increasing burden of IBD, we conducted a comprehensive review of IBD in the existing literature. The following parameters were reviewed: background knowledge and current standard care for IBD, including natural history, epidemiology, pathogenesis, diagnosis, monitoring, and treatment. In addition, new imaging modalities and treatment options such as combined positron emission tomography and magnetic resonance enterography, new biologic agents, small-molecule therapy, biosimilar therapeutics, mesenchymal stem cell transplantation, and fecal microbiota transplantation, all of which have been introduced for IBD management, were reviewed. We also used the hospital-based as well as population-based Taiwan National Health Insurance Research Database to assess Taiwan-specific trends for comparison with global trends. ? 2018 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067241918&doi=10.1016%2fj.jfma.2018.07.005&partnerID=40&md5=bb4a67d077f03e739a315ead9e88b742 https://scholars.lib.ntu.edu.tw/handle/123456789/565648 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.07.005 | SDG/關鍵字: | biological product; biosimilar agent; corticosteroid; immunosuppressive agent; Janus kinase inhibitor; mercaptopurine; mesalazine; methotrexate; monoclonal antibody; phosphodiesterase IV inhibitor; tumor necrosis factor inhibitor; environmental factor; epidemic; fecal microbiota transplantation; heredity; histopathology; history; human; incidence; inflammatory bowel disease; lifestyle; magnetic resonance enterography; mesenchymal stem cell transplantation; pathogenesis; patient care; positron emission tomography; prevalence; Review; Taiwanese; factual database; global health; inflammatory bowel disease; nuclear magnetic resonance imaging; public health; Taiwan; Databases, Factual; Global Health; Humans; Incidence; Inflammatory Bowel Diseases; Magnetic Resonance Imaging; National Health Programs; Positron-Emission Tomography; Prevalence; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。